Novartis Cosentyx wins CHMP backing for adolescent HS indication
Novartis has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation of Cosentyx (secukinumab) for adolescents aged 12 and older with active moderate to severe hidradenitis suppurativa (HS) who have not responded adequately to conventional systemic therapy. The European Commission is expected to issue a formal decision within approximately two months.
If the EC grants approval, secukinumab would become the only IL-17A inhibitor authorised for adolescent HS in Europe, and the first innovative biologic made available to this age group for the indication in close to a decade. Hidradenitis suppurativa is a chronic inflammatory skin condition that causes recurring abscess-like lesions, frequently in sensitive anatomical areas, and can result in permanent scarring. Published literature cited by Novartis suggests more than half of all HS cases emerge during puberty, underscoring the gap the approval would address.
Evidence base and dosing rationale
The CHMP opinion rests on a pharmacokinetic extrapolation strategy rather than a dedicated adolescent efficacy trial. Novartis submitted evidence showing that weight-based dosing in patients aged 12 and over produces secukinumab exposure broadly comparable to that seen in adults enrolled in HS studies. Supporting data were drawn from adult HS and psoriasis clinical trials, PK modelling, and paediatric data from other approved Cosentyx indications including juvenile idiopathic arthritis subtypes and plaque psoriasis. The FDA approved Cosentyx for the same adolescent HS population in the United States earlier in 2026, so the European regulatory move aligns the two major markets.
Dr John Ingram, Clinical Professor at Cardiff University School of Medicine, described the CHMP opinion as "an important step toward addressing a meaningful gap in care for young people living with this challenging disease," citing the risk of irreversible scarring if the disease is not controlled during adolescence.
Market context and competitive positioning
The HS treatment landscape in Europe has historically been dominated by adalimumab, which AbbVie secured CHMP backing for in adolescent HS as long ago as 2016. A positive EC decision for Cosentyx would give prescribers a second biologic class option for younger patients, specifically an IL-17A inhibitor rather than a TNF blocker, potentially offering a meaningful alternative for those who have failed or are unsuitable for anti-TNF therapy.
Cosentyx is already approved across a broad portfolio of immune-mediated indications in adults, including psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, and polymyalgia rheumatica, giving Novartis an established commercial infrastructure for the drug in Europe. The HS indication for adults was added more recently, and extending to adolescents follows a pattern the company has used across other Cosentyx indications, building the paediatric label progressively once adult data are mature.
Broader competitive dynamics in the HS space are intensifying. Several late-stage programmes targeting IL-17 and other inflammatory pathways are in development across the industry, and label expansions into younger patient populations are increasingly a differentiating strategy for established biologics facing biosimilar pressure in their core adult segments. For Novartis, securing the adolescent HS label before biosimilar secukinumab products become widely available in Europe strengthens the branded franchise at a critical juncture.
The formal EC decision, if it follows the CHMP recommendation as is customary, would make Cosentyx the second biologic and the only IL-17A inhibitor for adolescent HS on the European market.